Development Pipeline For nearly 30 years, Genentech has excelled at transforming scientific discoveries into breakthrough therapies for patients. Today, Genentech's development pipeline focuses on oncology, immunology, and disorders of tissue growth and repair.

Pre-IND/Phase 1
Oncology	4 New Molecular Entities (TBA)¹	Cancer Therapies
	Apo2L/TRAIL	Cancer Therapy
	Topical Hedgehog Antagonist	Basal Cell Carcinoma
Immunology	New Molecular Entity (TBA)¹	Immunology
	BR3-Fc	Rheumatoid Arthritis
Phase 2
Oncology	Avastin®	Glioblastoma Multiforme¹
	Avastin® +/- Tarceva®	Second-Line Non-Small Cell Lung Cancer
	Omnitarg™	Ovarian Cancer
Immunology	2nd Generation Anti-CD20	Rheumatoid Arthritis
	Rituxan®	Relapsing Remitting Multiple Sclerosis
	Xolair®	Peanut Allergy
Tissue Growth & Repair	Topical VEGF	Diabetic Foot Ulcers¹
Phase 3
Oncology	Avastin™	Adjuvant Breast Cancer¹ First-Line Metastatic Breast Cancer* Second-Line Metastatic Breast Cancer¹ Adjuvant Colorectal Cancer Adjuvant Non-Small Cell Lung Cancer¹ First-Line Ovarian Cancer First-Line Pancreatic Cancer First-Line Renal Cell Carcinoma Hormone Refractory Prostate Cancer
	Rituxan®	Relapsed Chronic Lymphocytic Leukemia
	Tarceva®	Adjuvant Non-Small Cell Lung Cancer¹
	Tarceva® +/- Avastin®	Second-Line Non-Small Cell Lung Cancer
Immunology	Rituxan®	ANCA-Associated Vasculitis Lupus Nephritis Rheumatoid Arthritis (DMARD Inadequate Responders) Primary Progressive Multiple Sclerosis Systemic Lupus Erythematosus
	Xolair®	Pediatric Asthma
FDA Filing Prep
Oncology	Avastin®	First-Line Metastatic Breast Cancer First-Line Non-Small Cell Lung Cancer
	Herceptin®	First-Line Metastatic Breast Cancer in Combination With Taxotere
	Rituxan®	Indolent Front-Line Non-Hodgkin's Lymphoma
Awaiting FDA Action
Oncology	Avastin®	Relapsed Metastatic Colorectal Cancer
	Herceptin®	HER2-Positive Breast Cancer in the Adjuvant Setting
Immunology	Rituxan®	Rheumatoid Arthritis (Anti-TNF Inadequate Responders)
Tissue Growth & Repair	Lucentis™	Wet Form of Age-Related Macular Degeneration

As of February 17, 2006
¹ Preparing for Phase
* In combination with several chemotherapy regimens